DUN'S 100 - 2016

551 / 730

Medical Equipment /
Cosmetics
551
016 | DUN’S 100 DUN’S 100 | 2015
DUN’S 100 | 2016 2016 | DUN’S 100
Industrial Companies 46 3 Pharmaceuticals & Cosmetic
RANK
Perrigo Israel
From its beginnings as a packager of ge-
neric home remedies in 1887, Perrigo
Company plc, headquartered in Ireland,
has grown to become a leading global health-
care supplier. Perrigo develops, manufactures
and distributes over-the-counter (OTC) and
generic prescription (Rx) pharmaceuticals, nu-
tritional products and active pharmaceutical
ingredients (API), and has a specialty sciences
business comprised of assets focused on the
treatment of Multiple Sclerosis. The Company
is the world’s largest manufacturer of OTC
healthcare products for the store brand mar-
ket and an industry leader in pharmaceutical
technologies.
Perrigo’s mission is to offer uncompromised
“Quality Affordable Healthcare Products™,”
and it does so across a wide variety of prod-
uct categories primarily in the United States,
United Kingdom, Europe, Mexico, Israel and
Australia, as well as more than 40 other key
markets worldwide, including Canada, China
and Latin America.
Perrigo has over 13,000 employees worldwide.
Perrigo’s shares are dually listed on New York
Stock Exchange (NYSE), and the Tel Aviv Stock
Exchange (TASE). The company’s combined an-
nual revenue exceeded $5 billion in 2015.
Perrigo Israel
Perrigo Israel develops, manufactures and
markets Generic Pharmaceuticals and Active
Pharmaceutical ingredients (API’s).
Perrigo Israel has three manufacturing sites
worldwide – two in Israel and one in India – and
employs 1,100 highly trained staff, including
Ph.D.s and life sciences professionals. More
than two-thirds of the company’s sales are gen-
erated by export.
Perrigo Israel – International Operations
Perrigo API supplies leading global pharma-
ceutical companies with Active Pharmaceuti-
cal ingredients (API’s) used in manufacturing
pharmaceutical products, and Perrigo Israel
Pharmaceuticals, develops and manufactures
generic topical medications.
Perrigo Israel’s innovative R&D program lever-
ages the benefits of integrating chemistry, API’s
and topical drugs. The company’s commitment
to innovative R&D is unwavering. In order to
build up its global operations, boost sales
growth and profitability, and pursue product
development, Perrigo Israel invests substantial
amounts in R&D operations every year.
Perrigo Israel – Israeli Market Operations
Perrigo Israel is a diversified pharmaceutical
company that imports, markets and distributes
brand and generic drugs and pharmaceuticals
and medical diagnostic equipment. Perrigo Is-
rael represents and distributes several major
pharmaceutical companies in Israel including:
Aspen, Grifols, GSK, Mapa, Sandoz, Siemens
Healthcare.
Ongoing Strategy
Perrigo is dynamic, flexible and capable of
adapting swiftly to changing market demands.
The Company has created a track record of sales
and earnings growth and broader capabilities
to grow in the global generic pharmaceutical,
API and consumer healthcare markets. This
provides a platform to build shareholder value
by increasing long-term sales and profitability
growth.
Generating Financial Strength
Perrigo’s shares are traded on the NYSE and
the TASE. The company generates strong cash
flows, which enable it to invest in R&D and
future expansion, thus positioning Perrigo for
long-term development growth.
Esta b l i s h e d
1887 – Perrigo
1961 – Perrigo Israel
L i n e o f B u s i n ess
Pharmaceuticals, Active
Pharmaceutical Ingredients (API),
Food Additives, Nutritional Products
Diagnostic & Medical Equipment
l e a d i n g e x ecu t i v es
John. T Hendrickson Chief Executive Officer
Judy Brown EVP and Chief Financial Officer
Sharon Kochan EVP, General Manager
International
Itzhak Maayan V.P., Perrigo Company & CFO,
Perrigo International
29 Lehi St., Bnei Brak 5120050,
P.O.B. 2231, Bnei Brak 5112102
Tel: 972-3-5773700
Fax:972-3-5773500
Pa r e n t Co m pa n y
PERRIGO COMPANY PLC (NYSE: PRGO),
(TASE: PRGO)